human
monoclon
antibodi
hiv
emerg
virus
dimit
dimitrov
throughout
centuri
viral
diseas
kill
hundr
million
peopl
continu
million
die
past
smallpox
caus
variola
viru
influenza
kill
million
peopl
pandem
million
infect
hiv
sinc
first
case
epidem
report
million
die
aid
although
vaccin
remain
costeffect
way
prevent
viral
infect
mani
case
eg
hiv
vaccin
avail
case
avail
vaccin
modifi
frequent
counteract
viru
escap
eg
influenza
prophylaxi
treatment
case
critic
import
fight
virus
number
studi
shown
import
neutral
antibodi
recoveri
protect
viral
infect
sera
human
anim
contain
antibodi
wide
use
prophylaxi
therapi
viral
bacteri
diseas
sinc
late
serum
therapi
bacteri
infect
abandon
antibiot
becam
wide
avail
howev
polyclon
antibodi
prepar
continu
use
toxinmedi
infecti
diseas
venom
bite
serum
immunoglobulin
ig
continu
also
use
viral
diseas
treatment
avail
although
mostli
prophylaxi
either
prior
anticip
exposur
follow
exposur
infecti
agent
antibodi
product
licens
unit
state
prevent
treatment
viral
diseas
includ
human
ig
use
hepat
measl
virusspecif
polyclon
human
ig
cytomegaloviru
hepat
b
rabi
respiratori
syncyti
viru
rsv
vaccinia
varicellazost
viru
human
monoclon
antibodi
mab
synagi
polyclon
ig
also
use
variou
success
diseas
caus
human
virus
includ
parvoviru
lassa
viru
west
nile
viru
enterovirus
herp
simplex
viru
crimeancongo
hemorrhag
fever
viru
junin
viru
sarscov
hiv
although
serum
polyclon
antibodi
prepar
clinic
effect
mani
case
problem
relat
toxic
includ
risk
allerg
reaction
lottolot
variat
uncertain
dose
limit
use
mab
includ
chimer
animalhuman
human
fulli
human
mab
hmab
possess
lower
absent
immunogen
toxic
lottolot
variat
molecular
mechan
therapeut
efficaci
antibodi
easier
dissect
engin
improv
therapeut
properti
recent
mab
shown
clinic
success
human
mab
synagi
palivizumab
still
mab
viral
diseas
approv
clinic
use
us
food
drug
administr
wide
use
prevent
rsv
infect
neonat
immunecompromis
individu
recent
improv
howev
effect
treatment
alreadi
establish
infect
exampl
signific
differ
clinic
outcom
placebo
palivizumab
group
children
hospit
rsv
infect
addit
resist
develop
rel
quickli
recent
studi
found
f
generesist
mutat
anim
model
rsv
infect
cotton
rat
week
infect
includ
complet
resist
viru
develop
hmab
prophylaxi
treatment
diseas
caus
hiv
emerg
virus
still
initi
stage
chapter
review
hmab
potenti
prophylaxi
treatment
diseas
caus
sarscov
henipavirus
hendra
hev
nipah
niv
mostli
igg
discuss
unless
specif
note
otherwis
isotyp
also
could
use
frequent
use
format
includ
fab
singlechain
variabl
region
fragment
scfv
note
describ
final
possibl
implic
develop
effect
vaccin
discuss
demand
new
treatment
option
hiv
becom
increasingli
import
side
effect
expans
spread
drugresist
viru
within
infect
popul
limit
clinic
benefit
provid
avail
antihiv
drug
despit
promis
present
synagi
improv
variant
develop
effect
antibodybas
therapeut
hiv
present
especi
difficult
challeng
therapi
base
small
moleculebas
drug
eventu
fail
expans
drugresist
viru
popul
infect
individu
antibodybas
therapi
immun
problem
replic
spread
within
dens
pack
cellular
environ
reach
cell
per
ml
lymphoid
tissu
gut
spleen
lymph
node
antibodi
may
difficulti
prevent
celltocel
spread
viru
seemingli
impenetr
lymphoid
environ
fact
passiv
administr
antihiv
antibodi
human
immun
plasma
polyclon
antibodi
prepar
confer
best
modest
clinic
impact
unfortun
trial
complic
rel
absenc
highli
effect
concentr
hivneutr
activ
polyclon
prepar
use
prepar
contain
high
concentr
hmab
exhibit
potent
activ
vitro
nhmab
hand
result
measur
decreas
plasma
viru
concentr
howev
vivo
potenc
prepar
insuffici
complet
block
viru
replic
resist
viru
rapidli
emerg
despit
discourag
result
studi
suggest
antibodi
enhanc
vivo
potenc
could
profound
clinic
impact
major
question
whether
antibodybas
therapeut
provid
longterm
clinic
benefit
patient
establish
infect
compar
better
drug
current
clinic
use
specif
featur
antibodi
compar
drug
hiv
evolv
number
strategi
escap
neutral
evas
strategi
viru
polyclon
antibodi
elicit
infect
strategi
use
immun
system
gener
broadli
neutral
hmab
extens
review
thu
short
answer
question
perhap
possibl
outsmart
viru
engin
potent
antibodybas
therapeut
viru
yet
evolv
protect
strategi
discuss
ongo
effort
improv
potenti
clinic
util
alreadi
known
hmab
identifi
novel
potent
antibodi
hiv
hiv
entri
cell
initi
attach
viral
envelop
glycoprotein
env
host
cell
receptor
conform
chang
follow
enabl
enhanc
exposur
coreceptor
typic
bind
site
bind
viral
glycoprotein
coreceptor
subsequ
conform
chang
final
result
fusion
viral
cell
membran
case
requir
env
directli
interact
coreceptor
env
mediat
hiv
entri
viral
surfac
protein
expos
surround
environ
major
target
neutral
antibodi
potent
immunogen
envspecif
antibodi
gener
earli
week
product
infect
immun
typic
neutral
current
viru
isol
rather
neutral
earlier
isol
antibodi
isolatespecif
lack
broad
neutral
activ
viru
evolv
hide
conserv
epitop
escap
neutral
number
mechan
result
antibodi
gener
natur
infect
immun
nonneutr
neutral
isol
mab
report
recogn
epitop
small
number
exhibit
neutral
activ
primari
isol
differ
clade
denot
broadli
crossreact
neutral
hmab
bcnhmab
use
phage
display
b
cell
immort
sever
bcnhmab
identifi
hivinfect
patient
whose
sera
contain
high
titer
antibodi
six
major
class
antibodi
relev
bind
locat
properti
epitop
identifi
antibodi
bind
region
contain
bind
site
antibodi
bind
better
complex
alon
antibodi
carbohydratebind
antibodi
antibodi
antibodi
target
membraneproxim
extern
region
mper
antibodi
bind
epitop
best
character
potent
antibodi
hmab
select
phagedisplay
antibodi
librari
construct
bone
marrow
donor
bind
site
mask
variabl
loop
shield
n
glycan
region
limit
access
conserv
epitop
context
oligomer
env
could
explain
antibodi
specif
bind
site
bind
weakli
env
oligom
exhibit
weak
moder
neutral
activ
primari
isol
recent
two
novel
nmab
identifi
sequenti
antigen
pan
sap
purifi
env
ectodomain
anoth
phagedisplay
antibodi
librari
deriv
bone
marrow
three
longterm
nonprogressor
high
titer
bcnhab
antibodi
crossreact
env
primari
isol
exhibit
differenti
neutral
activ
isol
differ
clade
env
undergo
signific
conform
chang
bind
lead
exposur
structur
contain
epitop
portion
epitop
target
antibodi
best
character
antibodi
weakli
neutral
neutral
activ
increas
significantli
size
reduc
scfv
neutral
activ
potent
broadli
neutral
antibodi
also
increas
mani
case
decreas
size
scfv
fab
one
note
howev
isol
assay
includ
assay
base
spread
infect
peripher
blood
mononuclear
cell
pbmc
potent
fab
like
due
increas
avid
thu
interplay
avid
size
could
import
determin
neutral
activ
antibodi
mani
antibodi
identifi
three
linear
epitop
exhibit
broad
neutral
activ
extens
character
bind
peptid
contain
stretch
mper
rel
conserv
use
competit
antigen
pan
methodolog
sever
new
crossclad
reactiv
mab
identifi
neutral
varieti
primari
isol
pbmcinfecti
virusbas
assay
bind
conform
epitop
distinct
antibodi
sever
line
evid
antibodi
inhibit
infect
first
demonstr
antibodi
exert
select
pressur
human
suggest
inhibit
infect
second
concentr
plasma
patent
decreas
follow
administr
hmab
third
tripl
combin
nmab
higher
dose
delay
viral
rebound
cessat
antiretrovir
treatment
addit
number
experi
shown
antibodi
prevent
infect
monkey
see
ref
recent
review
natur
occur
antibodi
potent
broad
neutral
activ
could
improv
recent
scfv
improv
potenc
breadth
neutral
use
sap
methodolog
librari
mutant
two
scfv
exhibit
averag
twoto
threefold
lower
ic
scfv
identifi
scfv
mutant
librari
also
screen
surfac
plasmon
reson
techniqu
immobil
env
one
scfv
select
basi
higher
kinet
associ
rate
activ
evalu
epitop
may
avail
limit
time
bind
interact
coreceptor
antibodi
faster
bind
kinet
would
bind
effici
like
better
inhibitori
activ
develop
variou
construct
includ
fusion
protein
evalu
neutral
activ
hiv
evolv
number
strategi
escap
host
immun
surveil
promin
modif
env
thu
natur
occur
whole
antibodi
env
may
littl
chanc
significantli
affect
viral
replic
diseas
progress
also
evidenc
lack
sustain
signific
effect
clinic
trial
test
antibodi
mostli
due
rapid
gener
resist
mutant
remain
fundament
problem
antibodi
also
antiretrovir
drug
antibodi
compon
entri
machineri
engin
antibodi
fragment
deriv
antibodybas
inhibitor
occur
natur
viru
develop
defens
mechan
may
better
abl
control
viru
replic
although
mechan
inhibitori
escap
gener
resist
mutant
difficult
access
could
still
oper
challeng
fight
mechan
simultan
ensur
rel
long
halflif
biolog
effector
function
sever
direct
research
appear
promis
aspect
one
direct
involv
engin
antibodi
higher
bind
affin
conserv
epitop
smaller
size
current
known
antibodi
anoth
use
uniqu
featur
antienv
antibodi
eg
mimicri
receptor
engin
novel
bind
entiti
highbind
affin
mani
isol
third
consist
engin
novel
fusion
protein
contain
antibodybind
fragment
fourth
reli
use
antibodi
effector
function
includ
antibodydepend
cellular
cytotox
adcc
complement
increas
efficaci
vivo
yet
anoth
direct
research
aim
develop
antibodynanoparticl
conjug
nanoliposom
particular
abl
irrevers
inactiv
viru
cell
express
viral
protein
develop
novel
approach
may
also
fruit
futur
well
combin
exist
one
develop
antibodybas
hiv
inhibitor
use
yet
undiscov
principl
whether
research
direct
lead
clinic
use
antibodybas
inhibitor
hiv
infect
remain
unknown
howev
even
new
engin
antibodi
fail
inhibit
hiv
infect
clinic
use
way
still
basi
optim
endeavor
new
approach
prove
use
elsewher
final
one
note
bcnhmab
undergon
long
matur
process
differ
germlin
sequenc
ten
mutat
one
could
specul
gener
antibodi
vivo
follow
immun
unlik
lack
b
cell
express
surfaceassoci
ig
close
function
bcnhmab
may
repres
challeng
develop
effect
aid
vaccin
studi
requir
find
novel
approach
elicit
bcnhmab
vivo
sarscov
caus
worldwid
epidem
infect
human
fatal
rate
although
recent
outbreak
need
develop
potent
therapeut
vaccin
reemerg
sarscov
relat
viru
remain
high
import
sarscov
infect
lead
gener
potent
neutral
antibodi
affect
cours
infect
help
clear
viru
also
protect
uninfect
host
expos
viru
antibodi
neutral
viru
vitro
assay
detect
sarscovinfect
patient
mice
hamster
monkey
infect
viru
antibodi
also
protect
uninfect
anim
sarscov
infect
eg
passiv
transfer
immun
serum
naiv
mice
prevent
viru
replic
lower
respiratori
tract
follow
intranas
challeng
patient
infect
sarscov
also
treat
convalesc
patient
plasma
contain
polyclon
antibodi
improv
antibodi
prepar
suggest
batch
virusinactiv
hyperimmun
globulin
contain
five
six
time
higher
titer
sarscovspecif
antibodi
convalesc
plasma
produc
amaz
pace
research
sever
group
recent
develop
hmab
sarscov
spike
glycoprotein
neutral
viru
potenti
therapi
prophylaxi
sar
review
ref
recent
improv
method
epsteinbarr
viru
transform
human
b
cell
develop
base
cpg
oligonucleotid
cpg
increas
b
cell
immort
effici
use
select
hmab
specif
sarscov
protein
one
select
antibodi
specif
glycoprotein
viral
spike
effici
neutral
convalesc
serum
prevent
cytopath
effect
sarscov
ngml
inhibit
entri
pseudoviru
glycoprotein
urbani
isol
ic
howev
affect
signific
extent
pseudoviru
entri
mediat
isol
glycoprotein
even
enhanc
entri
viru
pseudotyp
glycoprotein
palm
civet
isol
mous
model
sarscov
infect
antibodi
prevent
viral
replic
lower
respiratori
tract
dose
reduc
upper
respiratori
tract
highest
dose
use
unfortun
data
vivo
neutral
activ
nhmab
select
studi
includ
potent
antibodi
neutral
concentr
ngml
lower
report
high
neutral
activ
two
hmab
format
indic
possibl
use
alon
combin
prophylaxi
treatment
sar
phage
display
technolog
increasingli
use
produc
high
affin
hmab
immun
librari
advantag
use
librari
b
lymphocyt
infect
immun
host
requir
recent
two
human
nonimmun
scfv
librari
contain
member
develop
b
cell
unimmun
donor
use
select
antibodi
purifi
fragment
contain
residu
one
select
antibodi
neutral
viru
microneutr
assay
concentr
low
nm
also
block
format
syncytia
could
contribut
spread
viru
vivo
although
significantli
higher
concentr
nm
epitop
overlap
bind
site
sarscov
receptor
suggest
possibl
mechan
neutral
prevent
viru
attach
receptor
given
prophylact
mice
dose
therapeut
achiev
human
viral
replic
reduc
assay
limit
one
note
condit
use
evalu
neutral
activ
differ
antibodi
studi
exactli
studi
describ
previous
later
thu
compar
activ
differ
antibodi
done
caution
unless
test
side
side
exactli
condit
three
neutral
hmab
also
select
anoth
larg
antibodi
librari
bound
recombin
fragment
compris
amino
acid
residu
also
bind
receptor
receptorbind
domain
rbd
ref
potent
hnmab
requir
residu
bind
antibodi
exhibit
vitro
neutral
activ
importantli
antibodi
show
neutral
activ
ferret
one
set
experi
ferret
inocul
either
viru
two
dose
low
tcid
high
tcid
viru
preincub
antibodi
mgml
low
dose
mgml
high
dose
anim
expos
virusantibodi
mixtur
almost
undetect
sarscov
lung
show
lung
lesion
day
shed
viru
throat
unlik
control
anim
treat
irrelev
antibodi
second
set
experi
antibodi
mgkg
administ
hour
challeng
viru
reach
serum
concentr
three
anim
fourth
one
three
ferret
high
antibodi
concentr
viru
shed
throat
complet
abolish
fourth
one
compar
control
group
anim
log
lower
mean
viru
titer
control
complet
protect
macroscop
lung
patholog
note
antibodi
dose
use
mgkg
less
one
mgkg
use
prevent
rsv
infect
infant
administ
month
result
suggest
potenti
use
prophylaxi
sarscov
infect
human
reduc
viru
replic
extent
ferret
howev
one
note
current
avail
anim
model
sarscov
infect
result
death
human
two
hmab
deriv
transgen
mice
human
ig
gene
evalu
murin
model
sarscov
infect
one
antibodi
bound
within
rbd
protein
amino
acid
residu
one
region
includ
residu
microneutr
assay
base
protect
cytopath
effect
ic
mice
receiv
mgkg
antibodi
prior
challeng
sarscov
complet
protect
viru
replic
lung
dose
low
mgkg
offer
signific
protect
antibodi
potenti
therapeut
research
tool
studi
plan
evalu
nhmab
potenti
clinic
use
recent
identifi
novel
crossreact
potent
sarscovneutr
hmab
use
fragment
contain
residu
select
antigen
pan
larg
human
antibodi
librari
construct
b
lymphocyt
healthi
volunt
fragment
previous
identifi
contain
rbd
major
sarscov
neutral
determin
potent
inhibit
smediat
cell
fusion
ic
pseudoviru
entri
ic
replic
infecti
viru
mice
complet
protect
mg
per
mous
zhu
et
al
unpublish
interestingli
antibodi
also
inhibit
entri
mediat
glycoprotein
isol
mutat
compar
middlel
phase
isol
neutraliz
known
potent
hmab
includ
bound
high
pm
avid
rbd
biacor
chip
compet
suggest
mechan
neutral
involv
competit
receptor
bind
glycoprotein
zhu
et
al
unpublish
epitop
antibodi
identifi
crystallographi
propos
possibl
vaccin
immunogen
retrovaccinolog
approach
design
vaccin
immunogen
neutral
antibodi
direct
inhibit
sarscov
entri
either
interf
typic
rbdreceptor
interact
mechan
includ
bind
portion
recent
human
scfv
identifi
recogn
epitop
protein
locat
within
amino
acid
antibodi
recogn
sar
pseudoviru
vivo
compet
sar
sera
bind
sarscov
equilibrium
dissoci
constant
k
nm
also
potent
neutral
activ
infect
pseudoviru
express
sarscov
protein
vitro
mechan
sarscov
infect
inhibit
could
includ
steric
hindranc
indirectli
prevent
viru
attach
receptor
bind
entri
intermedi
mechan
could
oper
vivo
lack
data
discuss
relat
antibodi
biolog
effector
function
confer
antibodi
fc
eg
adcc
niv
hev
close
relat
emerg
paramyxovirus
compris
henipaviru
genu
broad
speci
tropism
abil
caus
fatal
diseas
anim
human
distinguish
hev
niv
known
paramyxovirus
review
ref
biolog
safeti
level
pathogen
niaid
biodefens
research
agenda
zoonot
emerg
categori
c
prioriti
pathogen
could
use
bioterror
agent
current
therapeut
modal
treat
niv
hev
infect
vaccin
prevent
diseas
human
livestock
popul
exist
although
antibodi
respons
detect
infect
caus
virus
develop
hmab
specif
hev
niv
realiz
recent
report
identif
potent
neutral
hmab
target
viral
envelop
glycoprotein
g
use
highli
purifi
oligomer
solubl
hev
g
sg
glycoprotein
antigen
screen
larg
human
phagedisplay
librari
select
seven
fab
inhibit
variou
degre
cell
fusion
mediat
hev
niv
env
viru
infect
convers
potent
neutral
infecti
hev
fab
significantli
increas
cell
fusion
inhibitori
activityth
ic
decreas
approxim
also
except
potent
neutral
infecti
hev
complet
neutral
achiev
neutral
requir
inhibit
fusion
infect
correl
bind
fab
fulllength
g
measur
immunoprecipit
less
bind
sg
measur
elisa
biacor
compet
other
recent
identifi
function
receptor
hev
niv
indic
possibl
mechan
neutral
antibodi
antibodi
compet
suggest
bind
overlap
epitop
distinct
epitop
initi
attempt
local
epitop
measur
bind
panel
g
alanin
scan
mutant
identifi
two
mutant
significantli
decreas
bind
one
decreas
bind
g
result
suggest
specif
hev
niv
exhibit
variou
neutral
activ
first
hmab
identifi
virus
could
use
treatment
prophylaxi
diagnosi
research
reagent
aid
develop
vaccin
recent
matur
vitro
potent
crossreact
antibodi
neutral
infecti
niv
hev
ic
ngml
zhu
et
al
unpublish
develop
cell
line
produc
larg
amount
antibodi
test
anim
model
henipaviru
infect
success
like
could
clinic
use
human
interestingli
antibodi
sarscov
henipavirus
identifi
librari
contrast
hiv
mutat
compar
respect
germlin
sequenc
correl
abil
variou
vaccin
elicit
potent
crossreact
neutral
antibodi
virus
contrast
hiv
one
could
specul
human
nativ
repertoir
antibodi
bind
rel
high
affin
envelop
glycoprotein
emerg
virus
hiv
env
experi
requir
test
hypothesi
true
could
lead
novel
approach
design
effect
vaccin
hiv
virus
hmab
direct
sarscov
glycoprotein
henipaviru
g
glycoprotein
current
advanc
stage
develop
offer
best
hope
potenti
therapeut
antibodi
specif
sarscov
hev
niv
potenti
develop
clinic
use
product
prophylaxi
perhap
treatment
diseas
caus
infect
potent
viral
infect
specif
acut
control
dampen
viru
replic
rel
short
period
time
week
like
requir
host
immun
system
could
control
viru
replic
addit
antibodi
could
crossreact
thu
problem
neutral
resist
mutant
abl
evad
inhibitori
activ
immun
respons
signific
chronic
infect
high
level
viru
replic
eg
hiv
infect
note
caution
care
examin
candid
antibodi
therapeut
requir
possibl
infect
enhanc
effect
eg
ebola
anim
modeldepend
effect
well
case
although
rare
toxic
recent
studi
also
report
possibl
neutral
antibodi
enhanc
entri
sarscov
mechan
involv
antibodi
interact
conform
epitop
rbd
addit
known
case
antibodi
neutral
assay
current
use
evalu
vitro
activ
could
exhibit
potent
neutral
activ
vivo
thu
new
approach
develop
antibodi
test
also
effector
function
mediat
fc
includ
antibodydepend
direct
cytotox
complementmedi
immun
respons
howev
explor
antibodi
extens
evalu
anim
model
like
combin
antivir
drug
antibodi
small
molecul
would
allow
identif
best
candid
potenti
therapeut
rapid
progress
made
last
year
toward
develop
potent
neutral
hmab
emerg
virus
virus
biodefens
import
basi
acceler
develop
neutral
antibodi
next
year
test
anim
model
like
see
novel
even
potent
antibodi
sarscov
current
exist
one
could
use
alon
combin
exist
antibodi
anim
model
viral
diseas
evalu
toxic
human
clinic
trial
current
avail
hmab
niv
hev
like
test
anim
success
like
undergo
evalu
human
clinic
trial
although
interest
bigand
mediums
compani
antibodi
appear
rel
minor
small
compani
startup
could
interest
develop
antibodi
provid
continu
government
support
program
like
bioshield
five
year
like
least
sever
hmab
potenti
clinic
use
case
outbreak
terror
attack
antibodi
could
use
combin
therapeut
increas
potenc
cope
resist
sever
key
issu
list
continu
research
develop
fund
acceler
pace
critic
import
develop
potent
clinic
use
therapeut
antibodi
phage
display
techniqu
well
novel
methodolog
critic
develop
fulli
human
antibodi
clone
express
purif
novel
antigen
screen
human
antibodi
librari
critic
import
crystal
structur
antibodi
complex
viru
envelop
glycoprotein
use
improv
antibodi
understand
interact
critic
import
develop
appropri
novel
anim
model
would
critic
import
acceler
test
therapeut
antibodi
necessari
understand
pathogenesi
design
antibodi
act
multipl
mechan
increas
efficaci
vivo
critic
import
evalu
combin
antibodi
antivir
drug
critic
import
acknowledg
studi
support
nih
nci
ccr
intramur
program
gate
foundat
nih
intramur
aid
program
iatap
nih
intramur
biodefens
program
